Related Experiment Videos
Methotrexate-vindesine association in leukemia: pharmacokinetic study
Medical Oncology and Tumor Pharmacotherapy
|January 1, 1985
Summary
This study investigated drug interactions between methotrexate (MTX) and vindesine (VDS) in acute lymphoblastic leukemia patients. Results show VDS does not affect MTX levels in cerebrospinal fluid, ensuring therapeutic effectiveness.
Area of Science:
- Oncology
- Pharmacology
- Neuroscience
Background:
- Methotrexate (MTX) and vindesine (VDS) are effective in treating acute leukemia.
- Potential cellular interactions between MTX and VDS exist.
- High-dose MTX is used for blastic meningitis treatment and prevention.
Purpose of the Study:
- To determine if vindesine (VDS) administration alters methotrexate (MTX) clearance and uptake in cerebrospinal fluid (CSF).
- To investigate the pharmacokinetic interaction between MTX and VDS in acute lymphoblastic leukemia patients.
Main Methods:
- Assayed plasma pharmacokinetics and CSF influx of MTX and VDS.
- Administered high-dose systemic MTX with intravenous VDS bolus.
- Measured MTX concentration using enzymatic assay and VDS using radioimmunoassay.
Main Results:
- No significant interrelation or interaction was found between MTX and VDS.
- MTX levels in CSF remained therapeutically effective and were unaffected by VDS.
- VDS was detected in CSF, but its levels were not altered by MTX.
Conclusions:
- Intravenous vindesine does not impact methotrexate cerebrospinal fluid pharmacokinetics.
- Combined administration of MTX and VDS in acute lymphoblastic leukemia does not lead to clinically relevant pharmacokinetic interactions in the CNS.